Anthem Biosciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
3,302
- Stock Symbol
-
ANTHEM
- Share Price
-
$10.02
- (As of Thursday Closing)
Anthem Biosciences General Information
Description
Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutical products that address unmet needs and provide biological solutions to improve industrial performance in all areas. The company offers its CRDMO services to biotech, pharmaceutical, and other companies for the development of large and small drug molecules, and also runs a products business offering specialty ingredients like fermentation products, peptides, lipids, probiotics, APIs, biosimilars, etc. Its reportable segments are: Contract Research Development and Manufacturing Services (CRDMO), which derives maximum revenue, and Specialty Ingredients. Geographically, the company generates maximum revenue from Europe, followed by North America, India, and other regions.
Contact Information
Website
www.anthembio.comCorporate Office
- Number 49, F1&F2, Canara Bank Road, Hosur Rd, Electronics City Phase 1
- Bommasandra Industrial Area
- Bengaluru, Karnataka 560099
- India
Corporate Office
- Number 49, F1&F2, Canara Bank Road, Hosur Rd, Electronics City Phase 1
- Bommasandra Industrial Area
- Bengaluru, Karnataka 560099
- India
Anthem Biosciences Stock Performance
As of 19-Nov-2026, Anthem Biosciences’s stock price is $10.02. Its current market cap is $5.65B with 564M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.02 | $9.78 | $6.32 - $10.53 | $5.65B | 564M | 659K | $0.12 |
Anthem Biosciences Financials Summary
As of 30-Sep-2026, Anthem Biosciences has a trailing 12-month revenue of $221M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 4,945,273 | 3,784,710 | ||
| Revenue | 220,704 | 240,408 | 218,143 | 171,451 |
| EBITDA | 106,841 | 100,220 | 81,785 | 63,725 |
| Net Income | 66,219 | 66,972 | 53,367 | 44,369 |
| Total Assets | 383,793 | 363,455 | 328,221 | 287,566 |
| Total Debt | 4,286 | 5,715 | 13,247 | 28,601 |
Anthem Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anthem Biosciences Comparisons
Industry
Financing
Details
Anthem Biosciences Competitors (22)
One of Anthem Biosciences’s 22 competitors is Sai Life Sciences, a Formerly VC-backed company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sai Life Sciences | Formerly VC-backed | Hyderabad, India | ||||
| BioDuro-Sundia | Private Equity-Backed | Irvine, CA | ||||
| OneSource Specialty Pharma | Formerly VC-backed | Bengaluru, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany |
Anthem Biosciences Patents
Anthem Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023105497-A1 | Synthesis of glp-1 analogues | Inactive | 10-Dec-2021 | ||
| AU-2022297739-A1 | A method for preparation of glycolipid carboxylic acids | Pending | 25-Jun-2021 | ||
| EP-4358969-A2 | A method for preparation of glycolipid carboxylic acids | Pending | 25-Jun-2021 | ||
| EP-4358969-A4 | A method for preparation of glycolipid carboxylic acids | Pending | 25-Jun-2021 | ||
| US-20240318217-A1 | A method for preparation of glycolipid carboxylic acids | Active | 25-Jun-2021 | C12P19/26 |
Anthem Biosciences Signals
Anthem Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Anthem Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Anthem Biosciences FAQs
-
When was Anthem Biosciences founded?
Anthem Biosciences was founded in 2006.
-
Where is Anthem Biosciences headquartered?
Anthem Biosciences is headquartered in Bengaluru, India.
-
What is the size of Anthem Biosciences?
Anthem Biosciences has 3,302 total employees.
-
What industry is Anthem Biosciences in?
Anthem Biosciences’s primary industry is BPO/Outsource Services.
-
Is Anthem Biosciences a private or public company?
Anthem Biosciences is a Public company.
-
What is Anthem Biosciences’s stock symbol?
The ticker symbol for Anthem Biosciences is ANTHEM.
-
What is the current stock price of Anthem Biosciences?
As of 19-Nov-2026 the stock price of Anthem Biosciences is $10.02.
-
What is the current market cap of Anthem Biosciences?
The current market capitalization of Anthem Biosciences is $5.65B.
-
What is Anthem Biosciences’s current revenue?
The trailing twelve month revenue for Anthem Biosciences is $221M.
-
Who are Anthem Biosciences’s competitors?
Sai Life Sciences, BioDuro-Sundia, OneSource Specialty Pharma, Cipla, and Evotec are some of the 22 competitors of Anthem Biosciences.
-
What is Anthem Biosciences’s annual earnings per share (EPS)?
Anthem Biosciences’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process